Garlic: Molecular Regulation of Hepatic Function.
大蒜:肝功能的分子调节。
基本信息
- 批准号:7158343
- 负责人:
- 金额:$ 3.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-09-29 至 2010-09-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Garlic and two constituents of garlic, diallyl sulfide (DAS) and diallyl disulfide (DADS), show an ability to regulate transcriptional activity of a number of hepatic enzymes and have the potential to induce herb-drug interactions. Garlic and DAS both cause increased cytochrome P450 (CYP) gene transcription. Garlic and DADS have been shown to increase transcriptional activity of antioxidant enzymes, such as NAD(P)H quinone oxidorecutase (NQO-1), and glutathione S-transferase (GST). While garlic induction of enzymes is well documented, the molecular mechanism(s) that cause these important reactions is not known. Aim 1 is designed to show that garlic and DAS induce transcriptional regulation of Phase I enzymes by activation of the Constitutive Androstane Receptor (CAR). Aim 2 is designed to show that garlic and DADS regulate transcription of antioxidant enzymes via activation of the nuclear factor-E2 related factor 2 (Nrf2). CAR activation results in an increase in the quantity of transporters and enzymes responsible for hepatic bilirubin clearance. Aim 3 is designed to determine whether garlic treatment can increase bilirubin clearance in vivo, and provide an alternative treatment for patients suffering from jaundice and other digestive diseases.
性状(由申请人提供):大蒜和大蒜的两种成分二烯丙基硫化物(DAS)和二烯丙基二硫化物(DADS)显示出调节许多肝酶转录活性的能力,并有可能诱导草药-药物相互作用。大蒜和DAS均引起细胞色素P450(CYP 450)基因转录增加。大蒜和DADS已被证明可以增加抗氧化酶的转录活性,如NAD(P)H醌氧化还原酶(NQO-1)和谷胱甘肽S-转移酶(GST)。虽然大蒜对酶的诱导是有据可查的,但引起这些重要反应的分子机制尚不清楚。目的1旨在表明大蒜和DAS通过激活组成型雄甾烷受体(CAR)诱导I相酶的转录调节。目的2表明大蒜和DADS通过激活核因子E2相关因子2(Nrf 2)调节抗氧化酶的转录。CAR激活导致负责肝脏胆红素清除的转运蛋白和酶的数量增加。目的3是确定大蒜治疗是否可以增加体内胆红素清除率,并为患有黄疸和其他消化系统疾病的患者提供替代治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CRAIG D FISHER其他文献
CRAIG D FISHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CRAIG D FISHER', 18)}}的其他基金
Garlic: Molecular Regulation of Hepatic Function.
大蒜:肝功能的分子调节。
- 批准号:
7295923 - 财政年份:2006
- 资助金额:
$ 3.42万 - 项目类别:
Garlic: Molecular Regulation of Hepatic Function.
大蒜:肝功能的分子调节。
- 批准号:
7473778 - 财政年份:2006
- 资助金额:
$ 3.42万 - 项目类别:
相似海外基金
Bilirubin Catabolism induces Plasminogen-Activator Inhibitor 1 (PAI-1) worsening Metabolic Dysfunction
胆红素分解代谢诱导纤溶酶原激活剂抑制剂 1 (PAI-1) 恶化代谢功能障碍
- 批准号:
10750132 - 财政年份:2024
- 资助金额:
$ 3.42万 - 项目类别:
Heme-, Redox-, and CO-dependent Regulation of Heme Homeostasis
血红素稳态的血红素、氧化还原和CO依赖性调节
- 批准号:
10660290 - 财政年份:2023
- 资助金额:
$ 3.42万 - 项目类别:
Mitochondrial Dysfunction underlies treatment related hepatotoxicity in Hispanics with acute lymphoblastic leukemia
线粒体功能障碍是西班牙裔急性淋巴细胞白血病治疗相关肝毒性的基础
- 批准号:
10675403 - 财政年份:2023
- 资助金额:
$ 3.42万 - 项目类别:
A point of care-device for the determination of creatinine phosphokinase (CPK), the CPK Now
用于测定肌酸酐磷酸激酶 (CPK) 的护理点设备,CPK Now
- 批准号:
10822139 - 财政年份:2023
- 资助金额:
$ 3.42万 - 项目类别:
Targeting heme metabolism to initiate an immune response against breast cancer liver metastasis
靶向血红素代谢启动针对乳腺癌肝转移的免疫反应
- 批准号:
10669286 - 财政年份:2022
- 资助金额:
$ 3.42万 - 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10480649 - 财政年份:2022
- 资助金额:
$ 3.42万 - 项目类别:
Targeting heme metabolism to initiate an immune response against breast cancer liver metastasis
靶向血红素代谢启动针对乳腺癌肝转移的免疫反应
- 批准号:
10523842 - 财政年份:2022
- 资助金额:
$ 3.42万 - 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10616658 - 财政年份:2022
- 资助金额:
$ 3.42万 - 项目类别: